RET and neoplasm: Lenvatinib is a multi-targeted tyrosine kinase inhibitor that significantly inhibits tumor angiogenesis and tumor cell proliferation by targeting signaling pathways such as VEGFR1-3, FGFR1-4, PDGFRα, RET and KIT.